Chronic Idiopathic Constipation CIC Drugs

Chronic Idiopathic Constipation CIC Drugs Market Outlook

The global Chronic Idiopathic Constipation (CIC) drugs market is projected to reach approximately USD 5.7 billion by 2035, growing at a CAGR of around 6.2% during the forecast period from 2025 to 2035. This growth is largely driven by an increasing prevalence of gastrointestinal disorders, a rise in awareness regarding treatment options, and advancements in drug formulations tailored for patients suffering from CIC. Furthermore, the expanding geriatric population, who are more susceptible to constipation issues, is expected to bolster the demand for effective CIC drugs. Innovations in drug delivery systems and the introduction of novel therapeutics are also anticipated to contribute to market growth, providing patients with more options to manage their symptoms effectively. The rise in healthcare expenditure and improvements in healthcare infrastructure globally also play a significant role in elevating the trajectory of the CIC drugs market.

Growth Factor of the Market

One of the primary growth factors for the Chronic Idiopathic Constipation (CIC) drugs market is the increasing prevalence of constipation-related disorders, which can be attributed to dietary habits, sedentary lifestyles, and rising stress levels among the population. Furthermore, the growing number of healthcare initiatives focused on educating patients about gastrointestinal health is leading to a higher diagnosis rate of CIC, thereby increasing demand for respective treatments. Advances in pharmacological research have also spurred the development of new, more effective drugs that cater specifically to CIC symptoms, enhancing patient outcomes and compliance. The rise in telemedicine and digital healthcare platforms is making it easier for patients to access treatments and consultations, further driving market growth. Additionally, the expansion of online pharmacies has revolutionized the distribution and accessibility of CIC medications, allowing patients to obtain treatments conveniently and discreetly.

Key Highlights of the Market

• The CIC drugs market is projected to reach USD 5.7 billion by 2035.
• The market is anticipated to grow at a CAGR of 6.2% during the forecast period from 2025 to 2035.
• Increased awareness and improved diagnostic tools contribute significantly to market growth.
• Advancements in drug formulation and delivery mechanisms are enhancing treatment options.
• The rising geriatric population is expected to amplify market demand for CIC medications.

By Product Type

Laxatives:

Laxatives represent one of the most commonly used categories in the treatment of Chronic Idiopathic Constipation (CIC). They function by promoting bowel movements through various mechanisms, such as increasing the water content of feces and stimulating intestinal motility. The laxative segment is further divided into osmotic laxatives, stimulant laxatives, and bulk-forming laxatives, catering to a broad spectrum of patient needs. The growing trend towards self-medication and the availability of over-the-counter laxatives have significantly contributed to their market share. Furthermore, consumer preference for natural and herbal remedies is shaping the development of more organic laxative options, which is attracting a wider audience seeking alternative treatments. The increasing number of patients diagnosed with CIC is expected to bolster the demand for laxatives, solidifying their role in the market.

Prosecretory Agents:

Prosecretory agents are a targeted treatment option for Chronic Idiopathic Constipation, functioning by enhancing fluid secretion in the intestines, thereby facilitating easier bowel movements. This category includes drugs such as linaclotide and plecanatide, which have gained traction due to their efficacy and favorable side effect profiles. The prosecretory agent segment is witnessing robust growth as more healthcare providers recommend these therapies for patients who do not respond adequately to traditional laxatives. Clinical studies demonstrating the success of these agents in short- and long-term management of CIC have further solidified their market presence. Additionally, awareness campaigns aimed at educating both healthcare professionals and patients about the benefits of these agents are contributing to increased acceptance and usage, propelling this segment's growth.

Lubiprostone:

Lubiprostone is a specific drug that has carved out a niche in the treatment of Chronic Idiopathic Constipation as it acts by increasing intestinal fluid secretion through the activation of chloride channels in the gastrointestinal tract. Its unique mechanism makes it particularly effective for patients who have not responded to conventional treatments. The rise in prescriptions for lubiprostone is reflective of healthcare providers' growing confidence in its efficacy and safety profile. Moreover, the increasing availability of lubiprostone as a name-brand and generic option enhances its market penetration. The patient demographic benefiting from lubiprostone is expanding, particularly among women and older adults, who are more prone to chronic constipation issues. This increasing awareness and successful clinical outcomes are contributing to the sustained growth of this product type in the CIC drugs market.

Linaclotide:

Linaclotide has gained prominence as an effective treatment for Chronic Idiopathic Constipation due to its dual action in both relieving constipation and alleviating associated abdominal pain. This medication works by enhancing gastrointestinal motility and secretion, allowing for more regular bowel movements. The growing body of clinical evidence supporting the benefits of linaclotide in diverse patient populations is driving its adoption among healthcare providers. Patients frequently report a significant improvement in quality of life upon using linaclotide, which has led to increased demand. Additionally, as pharmaceutical companies continue to market linaclotide effectively, including through patient education initiatives, its recognition as a frontline therapy for CIC is likely to further enhance its market position. The segment continues to thrive as more individuals seek targeted treatments for managing their chronic constipation symptoms.

Others:

The 'Others' segment in the Chronic Idiopathic Constipation drugs market includes a variety of alternative therapies and compounds that may not fit neatly into the primary categories discussed. This may encompass herbal remedies, dietary supplements, and experimental drugs that are in various stages of clinical development. As patients increasingly seek holistic treatment options, the demand for these alternative therapies is steadily rising. Moreover, ongoing research into the efficacy of these options is creating new market pathways, as successful products emerge from clinical trials. While this segment currently represents a smaller portion of the overall market, it holds significant potential for growth as consumer interest in natural and less invasive treatment methods continues to expand. The diversification of treatment options available to patients suffering from CIC underscores the evolving landscape of gastrointestinal health management.

By Application

Hospitals:

Hospitals play a crucial role in the administration of Chronic Idiopathic Constipation (CIC) treatments, providing comprehensive care for patients with more severe symptoms or those requiring specialized evaluation. In a hospital setting, patients are often offered a multi-faceted approach that may include pharmacological treatments, dietary consultations, and lifestyle modifications. The demand for CIC drugs within hospitals is driven by the higher patient turnover and the need for acute care solutions. As hospitals are increasingly equipped with advanced diagnostic tools, they can effectively identify and treat CIC patients, contributing to the growth of this application segment. Furthermore, the collaborative efforts of gastroenterologists and primary care physicians in hospitals enhance patient outcomes and promote the use of innovative therapies, thereby solidifying the importance of hospitals in the CIC drugs market.

Clinics:

Clinics serve as a pivotal point of access for patients seeking relief from Chronic Idiopathic Constipation, offering personalized treatment plans tailored to individual needs. With shorter wait times and more focused consultations, clinics provide an environment conducive to thorough evaluations and timely interventions. The growth of specialized gastroenterology clinics has further enhanced access to CIC treatment, as these facilities often employ a multidisciplinary approach to address underlying causes and recommend appropriate therapies. The convenience of visiting a clinic for consultation and follow-up has made this an appealing option for many patients. Additionally, as clinics increasingly adopt digital health technologies for patient monitoring and follow-ups, the effectiveness of treatment regimens for CIC is likely to improve, driving demand for relevant pharmaceuticals in this application area.

Retail Pharmacies:

Retail pharmacies are a key distribution point for Chronic Idiopathic Constipation (CIC) drugs, providing over-the-counter and prescription options to the general public. The convenience of accessing medications directly from retail establishments has significantly increased patient adherence to treatment regimens. With the growing prevalence of constipation issues, pharmacies are enhancing their inventory of CIC medications, ensuring that patients have access to both traditional laxatives and newer agents like lubiprostone and linaclotide. Moreover, pharmacists play an essential advisory role, guiding patients on appropriate product selection and usage. This accessibility and personalized service at retail pharmacies contribute to the overall growth of the CIC drugs market as they empower patients to take control of their gastrointestinal health.

Online Pharmacies:

The rise of online pharmacies has transformed the way patients access Chronic Idiopathic Constipation (CIC) medications, offering a convenient and discreet alternative to traditional purchasing methods. With the increasing trend towards e-commerce, patients can easily obtain their prescriptions or over-the-counter drugs from the comfort of their homes. This growth is further fueled by the COVID-19 pandemic, which accelerated the adoption of digital health solutions and online purchasing. Online pharmacies often provide greater price transparency, allowing patients to compare costs and make informed choices about their treatments. The convenience of home delivery services has also enhanced patient compliance, as individuals can receive their medications without the need for in-person visits. As online pharmacies continue to expand their reach, the market for CIC drugs is poised to benefit from this shift in consumer behavior.

By Distribution Channel

Prescription-based:

The prescription-based distribution channel is vital for the Chronic Idiopathic Constipation (CIC) drugs market, particularly for medications that require a healthcare provider's evaluation before use. This segment primarily includes prosecretory agents and specialized treatments that necessitate a thorough understanding of the patient's medical history. As healthcare practitioners gain more knowledge about the available treatment options for CIC, there is an increasing propensity to prescribe these medications, thus driving growth in this channel. The stringent regulations surrounding prescription medications ensure that patients receive the appropriate therapies tailored to their specific conditions. Additionally, the increasing collaboration between gastroenterologists and primary care physicians is leading to more effective management of CIC, which further supports the demand for prescription-based treatments.

Over-the-Counter:

The over-the-counter (OTC) distribution channel is rapidly evolving in the Chronic Idiopathic Constipation (CIC) drugs market, as more patients prefer to manage their symptoms independently. This segment includes a range of laxatives and other supportive treatments that do not require a prescription, providing immediate accessibility for consumers. The growing trend towards self-medication, combined with increased awareness of gastrointestinal health, has bolstered the demand for OTC options. Retail pharmacies and online platforms are expanding their offerings of OTC CIC treatments, making it easier for individuals to find suitable solutions. Moreover, marketing strategies that educate consumers about the safe and effective use of OTC drugs are encouraging more patients to seek these options for their constipation issues. As a result, the OTC segment is anticipated to see continued growth as more individuals take charge of managing their symptoms.

By Ingredient Type

Polyethylene Glycol:

Polyethylene glycol (PEG) is one of the most widely used ingredients in the formulation of OTC laxatives for Chronic Idiopathic Constipation. Known for its ability to retain water in the intestines, PEG helps to soften stool and promote regular bowel movements. This ingredient is highly valued for its safety profile and effectiveness, making it a first-line treatment option for many patients. As consumer awareness of PEG-based products increases, its market presence continues to expand, particularly among individuals seeking a gentle yet effective solution for constipation. Moreover, the growing trend of patients opting for non-invasive treatment alternatives is further propelling the demand for PEG formulations, which are effective without the risk of dependency that can accompany stimulant laxatives.

Prucalopride:

Prucalopride is a medication that highlights the innovation in the Chronic Idiopathic Constipation drugs market as a selective serotonin receptor agonist designed specifically for patients who have not found relief from standard treatments. Its unique mechanism of action enhances colonic motility, providing a viable alternative for those with chronic symptoms. The increasing clinical recognition of prucalopride's efficacy is expanding its use among healthcare providers, who are encouraged by the positive outcomes reflected in patient reports. As awareness about this medication continues to grow, it is likely to gain a more substantial share of the CIC drug market, particularly among patients with refractory constipation. The support of clinical studies validating its effectiveness is also contributing to the ongoing prescription of prucalopride as a reliable treatment option.

Plecanatide:

Plecanatide is another significant ingredient in the CIC drugs landscape, functioning as a prosecretory agent that stimulates intestinal fluid secretion. Its development is aimed at addressing the needs of patients with chronic idiopathic constipation who require more than just laxatives. Clinical evidence supporting plecanatide's efficacy has been instrumental in its growing acceptance among healthcare professionals. The medication is well-tolerated by patients, which enhances its attractiveness as a long-term treatment option. As the understanding of plecanatide’s mechanism continues to be disseminated among healthcare practitioners, the ingredient is expected to establish itself as a valuable asset in the management of CIC, reinforcing its position in the competitive landscape of CIC drugs.

By Region

The North American Chronic Idiopathic Constipation (CIC) drugs market is leading in terms of revenue generation, accounting for over 40% of the global market share in 2023. The United States is the primary contributor to this growth, driven by a high prevalence of gastrointestinal disorders, advanced healthcare infrastructure, and a well-established pharmaceutical industry. The demand for CIC medications is further supported by a growing awareness of gastrointestinal health among consumers and healthcare providers alike, promoting early diagnosis and treatment. The North American market is projected to grow at a CAGR of 6.5% from 2025 to 2035, indicating robust potential for expansion as new therapies continue to enter the market and existing treatments gain traction.

In Europe, the Chronic Idiopathic Constipation drugs market is also experiencing significant growth, driven by the rising geriatric population and the increasing prevalence of chronic health conditions that contribute to constipation. The European market is expected to account for approximately 30% of the global CIC drugs market by 2035, with countries such as Germany, France, and the United Kingdom showing substantial growth potential. As healthcare systems across Europe focus on improving patient outcomes through advanced treatment options, the demand for CIC drugs is anticipated to rise. The market in Asia Pacific is rapidly evolving, with a projected CAGR of 7.0%, reflecting an upsurge in awareness and prescription of CIC medications in countries like China and India as their healthcare systems develop. The cumulative growth across these regions reinforces the global trajectory of the CIC drugs market.

Opportunities

One of the significant opportunities in the Chronic Idiopathic Constipation (CIC) drugs market lies in the enhancement of telehealth services that are concurrently redefining patient care landscapes. With an increasing number of healthcare providers offering virtual consultations, patients are more likely to seek treatment for gastrointestinal issues without the barriers of traditional in-person visits. This shift not only broadens the patient base for CIC medications but also enables pharmaceutical companies to engage with a more extensive demographic through digital marketing and education initiatives. Furthermore, as telehealth continues to gain acceptance, it paves the way for innovative treatment options that can be prescribed and managed remotely, opening doors for continued growth in the CIC drugs sector.

Another opportunity arises from the ongoing advancements in drug formulation technologies. Pharmaceutical companies are actively investing in research and development aimed at producing more effective and targeted therapies for CIC, including biologics and personalized medicine approaches. The rise of precision medicine can lead to tailored treatment plans based on individual patient profiles, enhancing efficacy and patient satisfaction. As these innovations emerge, they are likely to capture the interest of both healthcare professionals and patients, contributing to the overall growth of the CIC drugs market. Additionally, the strategic partnerships between pharmaceutical companies and healthcare providers can facilitate faster delivery of new therapies to the market, making it possible to address unmet medical needs more effectively.

Threats

Despite the positive growth trajectory of the Chronic Idiopathic Constipation (CIC) drugs market, several threats loom on the horizon. A significant concern is the increasing competition from alternative treatment options, including lifestyle changes and over-the-counter remedies that may deter patients from seeking prescribed therapies. As more individuals turn to non-pharmacological approaches for managing their symptoms, pharmaceutical companies could experience a decline in demand for prescription medications. Additionally, the rise of consumer-driven healthcare may empower patients to opt for self-medication without professional guidance, potentially reducing the overall market for CIC drugs. This trend is compounded by the growing skepticism surrounding pharmaceutical products, as patients increasingly seek transparency and reassurance about the safety and efficacy of their treatments.

Furthermore, regulatory challenges pose a risk to the Chronic Idiopathic Constipation drugs market, as stringent guidelines may limit the availability of certain medications. The lengthy approval process for new drugs can result in delayed entry into the market, hampering innovation and limiting treatment options for patients. Additionally, changes in healthcare policies and reimbursement rates can directly impact the affordability and accessibility of CIC medications. These factors create an environment of uncertainty that may affect investment and growth opportunities within the CIC drugs market, necessitating strategic adaptation by industry players to navigate the evolving landscape.

Competitor Outlook

• Allergan
• AbbVie Inc.
• Ironwood Pharmaceuticals
• Takeda Pharmaceutical Company
• Pfizer Inc.
• Roche
• Horizon Therapeutics
• Salix Pharmaceuticals
• Sun Pharmaceutical Industries Ltd.
• Meda Pharmaceuticals Inc.
• Progenics Pharmaceuticals
• Valeant Pharmaceuticals
• GSK (GlaxoSmithKline)
• Janseen Pharmaceuticals
• Boehringer Ingelheim

The competitive landscape of the Chronic Idiopathic Constipation (CIC) drugs market is characterized by the presence of several key players actively engaged in the development and marketing of innovative therapies. Companies like Allergan and AbbVie Inc. lead the market with their well-established portfolios that include some of the most recognized treatments for CIC, such as linaclotide and lubiprostone. The competitive environment is further intensified by continuous research and development efforts aimed at enhancing drug efficacy and patient compliance. As the demand for CIC treatments rises, these companies are likely to increase their investment in clinical trials and partnerships to expedite the release of novel products. Furthermore, the emphasis on patient-centric approaches is steering firms towards developing personalized therapies that cater to the diverse needs of patients suffering from CIC.

Ironwood Pharmaceuticals is a notable competitor that focuses on advancing medical options for patients with gastrointestinal disorders, including CIC. Their flagship product, linaclotide, has gained significant traction in the market, due to its proven efficacy in treating constipation symptoms. The company's commitment to research and education initiatives aimed at increasing awareness of CIC among healthcare providers and patients is bolstering its market position. Meanwhile, Takeda Pharmaceutical Company and Pfizer Inc. are also key players that leverage their extensive global reach and resources to enhance their presence in the CIC drugs market. Their strategic partnerships and collaborations with healthcare facilities provide them with the opportunity to expand their product offerings and cater to a broader patient demographic.

In addition to these established companies, emerging players like Horizon Therapeutics and Progenics Pharmaceuticals are beginning to carve out their niche in the CIC drugs market by focusing on innovative solutions that address unmet medical needs. These companies are investing in clinical trials to demonstrate the efficacy and safety of their new therapies, which can significantly impact their market share. The overall landscape remains dynamic, with continuous competition fostering advancements in drug formulations and treatment options. As the CIC drugs market evolves, these competitive forces will shape the direction of future developments, ensuring that patient care and satisfaction remain at the forefront of industry efforts.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Roche
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 Allergan
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 AbbVie Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Boehringer Ingelheim
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Horizon Therapeutics
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 GSK (GlaxoSmithKline)
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Salix Pharmaceuticals
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Janseen Pharmaceuticals
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 Valeant Pharmaceuticals
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 Ironwood Pharmaceuticals
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Meda Pharmaceuticals Inc.
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Progenics Pharmaceuticals
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 Takeda Pharmaceutical Company
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Sun Pharmaceutical Industries Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Chronic Idiopathic Constipation CIC Drugs Market, By Application
    • 6.1.1 Hospitals
    • 6.1.2 Clinics
    • 6.1.3 Retail Pharmacies
    • 6.1.4 Online Pharmacies
  • 6.2 Chronic Idiopathic Constipation CIC Drugs Market, By Product Type
    • 6.2.1 Laxatives
    • 6.2.2 Prosecretory Agents
    • 6.2.3 Lubiprostone
    • 6.2.4 Linaclotide
    • 6.2.5 Others
  • 6.3 Chronic Idiopathic Constipation CIC Drugs Market, By Ingredient Type
    • 6.3.1 Polyethylene Glycol
    • 6.3.2 Prucalopride
    • 6.3.3 Plecanatide
  • 6.4 Chronic Idiopathic Constipation CIC Drugs Market, By Distribution Channel
    • 6.4.1 Prescription-based
    • 6.4.2 Over-the-Counter

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Chronic Idiopathic Constipation CIC Drugs Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Chronic Idiopathic Constipation CIC Drugs market is categorized based on

By Product Type

• Laxatives
• Prosecretory Agents
• Lubiprostone
• Linaclotide
• Others

By Application

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies

By Distribution Channel

• Prescription-based
• Over-the-Counter

By Ingredient Type

• Polyethylene Glycol
• Prucalopride
• Plecanatide

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Allergan
• AbbVie Inc.
• Ironwood Pharmaceuticals
• Takeda Pharmaceutical Company
• Pfizer Inc.
• Roche
• Horizon Therapeutics
• Salix Pharmaceuticals
• Sun Pharmaceutical Industries Ltd.
• Meda Pharmaceuticals Inc.
• Progenics Pharmaceuticals
• Valeant Pharmaceuticals
• GSK (GlaxoSmithKline)
• Janseen Pharmaceuticals
• Boehringer Ingelheim